Postdoc @BrighamWomens & @harvardmed Editor @NDTsocial My research: cardiorenal epidemiology, pharmacoepi, causal inference, trial emulation
Boston, MA
Joined January 2019
- Tweets1.3K
- Following2.2K
- Followers1K
- Likes2.2K
Pinned Tweet
Why did observational studies find ⬆️survival for late dialysis initiation, whereas the IDEAL RCT found no difference? Was it confounding, the usual culprit we point to? No!
Our new paper @bmj_latest addresses this and much more! #epitwitter #nephtwitter
bmj.com/content/375/bmj-2021…
🧵 Presented today at #ERA26:
In this observational study of adults in Stockholm, measured GFR (mGFR) values below 90 mL/min/1.73 m² were associated with progressively higher rates of #mortality, #kidney failure, #heart failure, acute kidney injury, and major #cardiovascular events.
ja.ma/4fqwGQB
Edouard L. Fu retweeted
4/ 7📈Measured versus estimated GFR and risk of adverse health outcomes. #ERA26
🎤 Edouard L. Fu @FuEdouard
📊 Across mortality and kidney failure outcomes, associations based on measured GFR (mGFR) were broadly similar to those obtained with modern eGFR equations, particularly cystatin C–based estimates.
⚠️ The key message: current CKD risk thresholds appear to remain clinically meaningful, even when tested against directly measured GFR. 🩺📉
Edouard L. Fu retweeted
Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) Project
bit.ly/44KGFu7 (OPEN ACCESS)
@AntoineCreon @meg21212 @FuEdouard @jjcarrero1
Edouard L. Fu retweeted
Research methods and reporting: How to align eligibility and treatment assignment at time zero when emulating a target trial.
This article provides methodological guidance when emulating a target trial with longitudinal observational data
@FuEdouard
bmj.com/content/392/bmj-2025…
Edouard L. Fu retweeted
Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
bmj.com/content/392/bmj-2025… via @FuEdouard et al
Edouard L. Fu retweeted
While target trial emulation cannot remove bias from inadequate data, it eliminates common biases induced by an incorrect design.
This article provides methodological guidance when emulating a target trial with longitudinal observational data
@FuEdouard
bmj.com/content/392/bmj-2025…
Edouard L. Fu retweeted
Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
bmj.com/content/392/bmj-2025… via @FuEdouard et al @RWJE_BA
📢 We’re hiring 2 PhD candidates @LUMC!
Help transform patient care by personalizing treatments for cardio‑kidney‑metabolic diseases using big data & causal inference.
We offer
🔹 Data from >20M patients
🔹 Cutting‑edge causal & ML methods
🔹 Collaborate w/ Karolinska & UCSF
🔹 Publish in top journals & shape global guidelines
🔹 Supportive, collaborative team + strong mentorship
👉 PhD 1 - MD background: lumc.nl/en/about-lumc/werken…
👉 PhD 2 - Data science/(Bio)statistics/Epidemiology background: lumc.nl/en/about-lumc/werken…
Edouard L. Fu retweeted
Trends in Major Cardiovascular Events and Bleeding Among Patients With Advanced CKD: A Nationwide Swedish Study
@meg21212 @FuEdouard @karin_modig @jjcarrero1
bit.ly/4osse52 #OpenAccess
ALT Temporal trends in the incidence rates of study outcomes in patients with advanced CKD and in the general population.
Edouard L. Fu retweeted
1/9🚨 Changing one formula could make 38% more people “have CKD” overnight.
That’s what happens if we replace the CKD-EPI equation with EKFC in a European health system.
👉 Our @NDTsocial paper shorturl.at/T5Dui
#CKD #GFR #nephtwitter
@jjcarrero1 @FuEdouard @PStoneOftheYear
Edouard L. Fu retweeted
Discordances Between Creatinine- and Cystatin C–Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice
bit.ly/4491HQp #OpenAccess
@jjcarrero1 @FuEdouard @Shoshana_Ballew @CarlElinder @LAInker @ASLtufts @meg21212
Edouard L. Fu retweeted
Finally, a good modern book on causality for ML: causalai-book.net/ by @eliasbareinboim. This looks like a worthy successor to the ground breaking book by @yudapearl which I read in grad school. (h/t @JoshuaSafyan for the ref).
Edouard L. Fu retweeted
🧵1/9
Could we improve kidney care by rethinking who gets referred to a nephrologist?
Our latest study from the SCREAM cohort suggests: yes — if we base it on predicted risk rather than fixed eGFR/ACR cutoffs.
📄 Caldinelli et al, 2025, @NDTsocial
🔗shorturl.at/0CzNq
Edouard L. Fu retweeted
Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease
bit.ly/Mazhar25OI #OpenAccess
#VisualAbstract
@FuEdouard @VladoPerkovic @KatherineTuttl8 @jjcarrero1
Edouard L. Fu retweeted
#GDMT has now arrived for #HFpEF
#SGLT2i (class I) and #nsMRA (class IIa) recommendations in initial global guidelines
jstage.jst.go.jp/article/cir…
#HeartFailure2025
🎶 Attending #ERA2025 in Vienna?
Don't miss Music & Kidney — a unique evening where classical music meets nephrology!
🗓️ Wednesday June 4 | 🕘 21:00 | 📍 Sofiensäle
🔗soundsandscience.com/index.p…
@ERAkidney @jjcarrero1 #MusicAndMedicine #Nephrology #ViennaEvents
The 24th Sounds and Science concert features:
🎼 Mozart’s Marriage of Figaro & Violin Sonata
🎼 Dvořák’s Sonatina & Slavonic Dance No. 2
🎙️ With talks on kidney immunology & the composers' lives by @PRomagnani
Hosted by nephrologists @EllerKathrin & @RainerOberbauer
Edouard L. Fu retweeted
*30 years* after the start of the RALES trial
the targeting of the MR axis remains one of the hottest areas of drug development across cardio-kidney-metabolism
Expected read-outs in '25:
#ACHIEVE sMRA in ESKD
#CONFIDENCE Combo nsMRA+SGLT2i in CKD
#SPIRITHF sMRA in HFmrEF/HFpEF
Edouard L. Fu retweeted
🔥 #CONFIDENCE closed out & selected as LBCT to headline #ERA25, led by #ProfRajivAgarwal
Largest RCT to test combination #SGLT2i empagliflozin & #nsMRA finerenone
Will 1+1 = 2?
Baseline: academic.oup.com/ndt/advance…
Design: academic.oup.com/ndt/article…
See you in Vienna 🇦🇹 @ERAkidney
